Because prostate cancer has a long latency and high incidence, it is a good target for chemoprevention by agents such as retinoids, antiandrogens, antiestrogens, and vitamin D analogs. Phase II chemoprevention trials are frequently conducted on cohorts of patients with previous cancers or premalignant lesions who are scheduled for prostate cancer surgery; such trials are currently in progress with several agents. Prostatic intraepithelial neoplasia (PIN) can be used as a surrogate endpoint biomarker for prostate cancer incidence. Studies of men with highgrade PIN (HGPIN) are particularly useful in that they require a much smaller cohort of 200±400 patients instead of the 18 000 patients required for typical Phase III trials. Even with a smaller sample size, statistically signi®cant evidence of cancer prevention is achieved due to the high probability of HGPIN progressing to cancer (35±55%). A Bayesian sequential monitoring system allows interim analysis of biomarker modulation as early as the completion of 30 patients. Putting all these strategies together will help inhibit, delay, or modulate the natural history of prostate carcinogenesis.
Introduction
Chemoprevention is the administration of agents (drugs, biologics and nutrients) to prevent induction of, inhibit, or delay progression of cancers. Because of its long latency and high incidence, prostate cancer is an important target for chemoprevention. 1, 2 As for other cancers, development of rational prostate chemopreventive strategies requires knowledge of major mechanisms of carcinogenesis in the tissue and identi®cation of agents that interfere with these mechanisms. 3±6 Also, to identify suitable populations for evaluation of potential chemopreventive agents and for future chemopreventive intervention, such risk factors as the presence of early premalignant lesions and genetic predisposition should be well-characterized. Because carcinogenesis takes place over a long time period, requiring large cohorts for evaluable studies, cancer incidence is usually not a feasible endpoint for chemoprevention clinical trials. 3±5 Therefore, chemopreventive agent development depends on identifying and characterizing early intermediate endpoints and validating them as surrogate endpoints for cancer incidence in clinical chemoprevention trials. Table 1 summarizes the various aspects of chemoprevention in prostate cancer.
4±6

Promising chemopreventive agents in prostate
An agent requires experimental or epidemiological data showing chemopreventive ef®cacy, safety on chronic administration, and a mechanistic rationale for the chemopreventive activity observed. 3±5 On this basis, promising chemopreventive agents in prostate include retinoids (for example, all-trans-N-4-(hydroxyphenyl)retinamide (4-HPR) and 9-cis-retinoic acid), RAMBA (retinoic acid metabolism blocking agent), vitamin E, organoselenium, lycopene, soy derivatives such as iso¯avones (for example, genistein)], 2-di¯uoromethylornithine (DFMO), steroid 5a-reductase inhibitors (for example, ®nasteride, dual type 1 and 2 inhibitors), apoptosis inducers (for example, perillyl alcohol), and differentiation agents (for example, vitamin D analogs). Of the agents proposed as chemopreventives in prostate, the best known is ®nasteride (Proscar 1 ), which inhibits the enzyme testosterone 5a-reductase. 7 In progress is a large Phase III clinical trial of ®nasteride in chemoprevention of prostate cancer which has enrolled 18 000 subjects (see Table 2 ). 8 Early experimental data suggested that retinoids such as 4-HPR or agents which inhibit retinoid metabolism such as RAMBA will be chemopreventive in the prostate, provided suf®-cient tissue levels are achieved. 9 The enzyme ornithine decarboxylase (ODC), which is associated with cellular proliferation, is found at high levels in the prostate and prostate neoplasms; 10 DFMO, an ODC inhibitor and potent antiproliferative agent, appears to be a promising chemopreventive agent. In a cohort with prior non-melanoma skin cancer, selenium in the form of selenized brewer's yeast (200 mg Se/d) was associated with a 63% reduction in prostate cancer compared with placebo controls. 11 Epidemiological studies suggest that increased serum levels of lycopene, the most abundant serum carotenoid, are associated with a decreased relative risk of prostate cancer.
12,13
Rationale for antiandrogens and antiestrogens as chemopreventive agents in prostate cancer
Testosterone's association with prostate cancer risk is well known; 14 both experimental and clinical data suggest antihormonal activity is a potential chemopreventive mechanism in the prostate. Chemopreventive strategies are being developed using antiandrogens (for example, utamide and bicalutamide, as well as steroid 5a-reductase inhibitors) and antiestrogens (for example, tamoxifen, toremifene, raloxifene, SERM-3 and steroid aromatase inhibitors). Bostwick and his colleagues 15 have recently described clinical protocols for using antiandrogens as 15 are currently carrying out a Phase II randomized controlled trial to test the hypothesis that coupling testicular with prostatic androgen blockade will be effective in slowing progression of PIN to prostate cancer. In this study, an LHRH antagonist (leuprolide) is administered in combination with an antiandrogen (¯utamide) for 12 weeks prior to prostatectomy, in a cohort with localized prostate cancer and concurrent high grade PIN (HGPIN). This treatment is used in some centers to shrink the prostate prior to surgery. The chemoprevention study compares grade, PIN area, and other biomarkers of prostate glands from patients who received the drug combination with glands from untreated controls. Bostwick and his colleagues suggest that the bene®ts of inducing PIN regression could outweigh the toxicity of this relatively short treatment period in high-risk subjects with HGPIN.
Vitamin D 3 analogs and prostate cancer inhibition
Both epidemiological and experimental studies have implicated vitamin D 3 in controlling the progression of prostate cancer. Epidemiological data show general correspondence between cancer incidences and low or de®-ciency levels of vitamin D, 18±20 as well as speci®c correlations of low vitamin D levels to subsequent diagnoses of prostatic carcinomas. 21 Studies in prostatic carcinoma cell lines (for example, LNCaP, DU-145, PC-3, ALVA-31) show that the cancer inhibitory effects of vitamin D 3 are its antiproliferative and differentiationinducing activities. Furthermore, these potentially chemopreventive activities appear to be mediated via the vitamin D receptor (VDr).
22±24 That is, inhibitory activity is higher in prostatic carcinoma cells with signi®cant levels of VDr and the capability of converting vitamin D 3 to its inactive metabolite 1,24,25-trihydroxyvitamin D 3 . 25 Some data suggest that cell cycle arrest in G 1 is an important mechanism for the antiproliferative activity 26 with induction of the cell cycle-dependent kinase inhibitor p21 being the molecular target of the VDr complex. 27 Another potential target is the suppression of Id gene expression (Id is an inhibitor of differentiation).
Induction of hypercalcemia is a well-known toxicity of vitamin D 3 , which limits its usefulness as a chemopreventive drug and has led to the development of synthetic analogs with greater differentiating potency and lower or equivalent hypercalcemic activity. Intermediate biomarkers/surrogate endpoints of prostate cancer Biomarkers must ®t expected biological mechanisms (that is, differential expression in normal and high-risk tissue, on or closely linked to the causal pathway for the cancer, modulated by chemopreventive agents, and short latency compared with cancer), may be assayed reliably and quantitatively, measured easily, and correlate to decreased cancer incidence.
3±5 Table 1 lists potentially important intermediate biomarkers for prostate cancer. As in other cancers, two types of prostate biomarkers, measures of the histological precancerous lesion PIN 30 and indicators of cellular proliferation kinetics, stand out in regard to their high correlation to cancer and their ability to be quanti®ed. Measurements made by computer-assisted image analysis (CAIA) that are potentially useful as assessments of chemopreventive ef®cacy include PIN nuclear polymorphism comprising nuclear size, shape (roundness), and texture (DNA distribution patterns); nucleolar size and number of nucleoli/nuclei; DNA ploidy; and proliferation biomarkers such as Sphase fraction, DNA labeling index, Ki-67, and proliferating cell nuclear antigen (PCNA). 5 Other possible biomarkers are associated with differentiation (for example, blood group antigens, vimentin), genetic damage (for example, chromosomal gain or loss), signal transduction regulators (for example, TGFa, c-erbB-2 expression), and biochemical changes (for example, PSA levels).
PIN as SEB for prostate cancer
The promise of PIN as a premalignant lesion and hence potential surrogate endpoint biomarker (SEB) for prostate cancer, and the characteristics of PIN progression, have been described recently by Brawer, Bostwick and their colleagues 30±38 Figure 1 depicts the progression of prostate epithelia from normal to early low grade PIN (LGPIN) to HGPIN to carcinoma. The evidence that PIN is a precancer includes morphology; the atypia observed in HGPIN is virtually indistinguishable from invasive cancer, except that in HGPIN the basal membrane is still intact. As PIN progresses, the likelihood of damage to the basal cell layer increases. PIN and prostate cancer share other phenotypic parameters. For example, certain cytoskeletal proteins, secreted proteins and degree of glycosylation are shared by PIN and cancer, but not by benign prostatic hyperplasia or normal prostate epithelium. Also, PIN is associated spatially and temporally with prostate cancer, both being found primarily in the peripheral zone, and with far less prevalence in the transition zone. Based on several studies in which whole prostates were obtained, HGPIN was seen in 32% (of 876) of specimens without cancer and in 73% (of 731) specimens with concomitant cancer. Increasing rates of aneuploidy and angiogenesis from low grade PIN to HGPIN to cancer also are evidence that PIN is a precancer. Table 2 shows grading criteria for PIN. Quantitative assessments of these features using CAIA (for example, for measuring nuclear pleiomorphism) may be particularly useful as SEB for prostate cancer. 3±5 Cohorts in these trials should be suitable for measuring chemopreventive activity of the agent and intermediate biomarkers chosen as endpoints. Also, many cohorts proposed for Phase II trials are composed of patients with previous cancers or premalignant lesions. For such patients, the trials are conducted within the context of standard treatment. For example, a cohort currently used in Phase II prostate cancer chemoprevention trials are patients scheduled for prostate cancer surgery. These patients are treated with the chemopreventive drug during the two-to eight-week period between diagnostic biopsy and prostatectomy. As shown in Table 3 , changes in various biomarkers between the diagnostic biopsy tissue and biopsy tissue taken after prostatectomy are evaluated. Trials following this protocol are currently in progress with DFMO, 4-HPR,¯utamide, ®nasteride, utamide ®nasteride, toremifene and selenomethionine/selenized yeast. A study of¯utamide leuprolide in the presurgical cohort with prostate cancer was described above. Another cohort for Phase II and early Phase III trials is patients with HGPIN without prostatic carcinoma. In this cohort, the primary endpoint is PIN regression and cancer incidence reduction, and the treatment period is up to three years. A trial of antiandrogen monotherapy (¯utamide) is now in progress in this PIN cohort. A Phase III trial of ®nasteride was cited above. 8 The cohort for this trial is essentially normal (PSA 3 ng/ ml, no evidence of cancer on DRE), but high-risk (age ! 55 y) men. Bostwick has described these and other potential cohorts for Phase II and III chemoprevention trials. 34 The other cohorts are men with prostate cancer for whom`watchful waiting' rather than surgery is prescribed and men at high risk because of elevated PSA (b4 ng/ml).
Clinical evaluation of chemopreventive drugs in prostate
Cancer risk and cohort selection
The cancer risk of the cohort or target population affects most aspects of the clinical study designÐincluding choice of investigational agent, control regimen, primary endpoint, sample size and statistical power (see Table 5 ). For example, the Phase III ®nasteride trial requires a very large cohort (18 000 men aged b25 y) to detect the clinical endpoint of 25% reduction in cancer incidence by seven years at 90% power. In contrast, Phase II/III studies in subjects with HGPIN may require only 200±450 subjects to detect the endpoint of 33±40% reduction in prostate cancer incidence within 1±3 years at 90% power. The marked reduction in sample size required to see a statistically signi®cant reduction in cancer incidence arises from the high probability of HGPIN progressing to cancer (35±55%).
30±38
Data analysis
The (1) correlation between the effect on the SEB and cancer incidence; (2) proportional magnitudes of changes in SEB and cancer incidence; (3) explanation by the SEB of a signi®cant fraction (50± 75%) of the treatment effect. 39 To improve the ef®ciency of new agent evaluation in randomized, controlled Phase II studies, we have adapted a Bayesian sequential monitoring scheme 40 for interim analysis of the modulation of selected intermediate biomarkers 41 as early as the completion of 30 patients. The Bayesian method is designed to stop quickly for ineffective agents but more slowly for active agents than conventional group sequential methods (for example, O'Brien-Fleming 42 ). The Bayesian approach allows interpretation to be more¯exible and simpler, but requires prior knowledge of the intermediate biomarker (mean and variance) and the typical treatment effect (mean and variance).
De®nition of endpoints
Statistical classi®cation of study endpoints (continuous vs discrete) and nature of the endpoint sampling (for example, use of paired samples, measuring change from baseline to posttreatment in the same sampling area, or use of unpaired samples in the posttreatment groups) are critical to achieving reliable evaluations. The number and location of samples from the invasive cancer, HGPIN, and adjacent normal-appearing tissue, as well as the thickness/number of histologic sections processed and scored are important parameters that affect variability, accuracy and reproducibility. 43 Since HGPIN is the best candidate surrogate endpoint for prostate cancer incidence in chemoprevention trials, the standardization of PIN assessment is critical. Current approaches for measuring effects on the prevalence and extent of HGPIN involve calculating the percent of patients with PIN. 43 Other promising methods include mapping area and volume of PIN (Bostwick, personal communication) and digital imaging of the prostate whole mount (Becich and Trump, personal communication).
Opportunities for chemopreventive intervention in prostate carcinogenesis
As suggested by the discussion above, there are many opportunities for inhibiting, delaying or modulating the natural history of prostate carcinogenesis. Examples of possible cohorts for chemopreventive intervention in Phase II and III trials are de®ned by risk factors and include (by increasing risk): age b50y; genetic polymorphism in 5a-steroid reductase 2 (SRD5A2); elevated PSA with no other indication; and HGPIN. SEBs are also de®ned by these risk factors. The expected bene®ts of using intermediate biomarkers in chemoprevention trials include enhanced identi®cation of high-risk groups, more rapid assessment of ef®cacy based on modulation of the 
